Melatonin therapy for REM sleep behavior disorder: a critical review of evidence.
Study Goal
The researchers aimed to evaluate the potential of melatonin as a treatment for REM sleep behavior disorder (RBD) compared to clonazepam, focusing on safety, efficacy, and tolerability.
Results Summary
Melatonin was found to reduce clinical behavioral outcomes and muscle tonicity during REM sleep in RBD patients, with a favorable safety and tolerability profile compared to clonazepam. The abstract suggests melatonin may be a viable alternative, especially for elderly patients on multiple medications.
Population
Individuals with REM sleep behavior disorder (RBD), particularly elderly patients receiving polypharmacy.
Effective Dosage
Not specified
Duration
Not specified
Interactions
Limited potential for drug-drug interactions mentioned, especially relevant for elderly patients on polypharmacy.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Clonazepam | neutral | Rapid eye movement (REM) sleep behavior disorder (RBD) | - | - | has long been suggested as the first-line treatment option | #1 |
Melatonin therapy | increase | evidence supporting | - | - | is expanding | #2 |
Melatonin | neutral | Rapid eye movement (REM) sleep behavior disorder (RBD) | - | - | appears to be beneficial for the management | #3 |
Melatonin | decrease | clinical behavioral outcomes | - | - | reductions in | #4 |
Melatonin | decrease | muscle tonicity during REM sleep | - | - | decrease in | #5 |
Melatonin | neutral | clonazepam | - | - | has a favorable safety and tolerability profile over | #6 |
Melatonin | decrease | drug-drug interactions | - | - | has limited potential for | #7 |
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia associated with dream enactment often involving violent or potentially injurious behaviors during REM sleep that is strongly associated with synucleinopathy neurodegeneration. Clonazepam has long been suggested as the first-line treatment option for RBD. However, evidence supporting melatonin therapy is expanding. Melatonin appears to be beneficial for the management of RBD with reductions in clinical behavioral outcomes and decrease in muscle tonicity during REM sleep. Melatonin also has a favorable safety and tolerability profile over clonazepam with limited potential for drug-drug interactions, an important consideration especially in elderly individuals with RBD receiving polypharmacy. Prospective clinical trials are necessary to establish the evidence basis for melatonin and clonazepam as RBD therapies.